Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 113715 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | PLACEBO_COMPARATOR | Sulfonylurea + 100 mg/week ISIS 113715 or placebo |
| B | PLACEBO_COMPARATOR | Sulfonylurea + 200 mg/week ISIS 113715 or placebo |
| Name | Type | Description |
|---|---|---|
| ISIS 113715 | DRUG | doses of 100 and 200 mg per week |
Inclusion Criteria: * Type 2 diabetes mellitus of less than or equal to eight years in duration, diagnosed according to American Diabetes Association criteria * Fasting serum glucose from 150 to 270 mg/dL at screening visit * HbA1c from 7.5 to 11.0 at screening * Being treated with at least 10 mg/d...
ISIS 113715 is an investigational drug being developed for the treatment of Type 2 Diabetes Mellitus. It is a small molecule being studied in clinical trials to evaluate its safety, tolerability, and activity in people with this condition. The drug is administered by subcutaneous injection and is currently in Phase 2 clinical development.
ISIS 113715 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
ISIS 113715 is in Phase 2 clinical development. It has completed three clinical trials, including two Phase 2 studies and one Phase 1 study. The drug is investigational and has not been approved by regulatory authorities. It remains in clinical development for the treatment of Type 2 Diabetes Mellitus.
ISIS 113715 has completed three clinical trials. NCT00330330 was a Phase 2 study in treatment-naive patients with Type 2 Diabetes Mellitus. NCT00365781 was a Phase 1 dermatologic effects study in healthy volunteers. NCT00455598 was a Phase 2 dose escalation study in patients treated with sulfonylurea. All trials are completed.
ISIS 113715 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being studied under this name in clinical trials for Type 2 Diabetes Mellitus.